Reshaping the HIV treatment and prevention landscape
GSK '294 (depemokimab): potential best-in-class long-acting IL-5 antagonist
with ambition to transform SEA treatment
gsk
High unmet need despite success of IL5s
-
-
>50m worldwide suffer with severe eosinophilic asthma
- ~27% of eligible patients on biologic therapy
- ~50% uncontrolled despite being on therapy
-
Low adherence (<60%) or treatment reluctance
due to lack of convenience or fear of injection
Ph3 ongoing with unique dosing frequency
-
-
High affinity and long-lasting suppression of IL-5
6-month SC* dosing attractive to patients
- Ph3 high probability of success (validated MoA)
- On track to be first long-acting biologic for SEA
-
Data expected in 2024
Dosing frequency
Approved biologics
Dupixent
Every 2 weeks
Nucala
Every 4 weeks
Fasenra
GSK'294
Every 8 weeks
Every 26 weeks
Potential to be the SEA treatment of choice
for continuing and new to biologics patients
₤1-2bn opportunity
* Subcutaneous
SEA Severe Eosinophilic asthma; MoA Mechanism of Action
97View entire presentation